May 15, 2025 — Abundant Venture Partners has launched the Abundant Platform to grow high value, sustainable companies that benefit healthcare provider organizations. The platform accelerates commercialization through the Abundant Venture Studio, ensures rapid adoption via the Abundant Alliance of healthcare providers, and drives scale with aligned, provider-backed seed and series A venture funds.

May 21, 2025 — RapidAI recently announced new study findings that show RapidAI’s clinically deep algorithms deliver superior accuracy in detecting medium vessel occlusions (MeVOs).

The data, presented as a late-breaking abstract at the European Stroke Organisation Conference (ESOC) 2025, analyzed 1,591 consecutive stroke cases at a comprehensive stroke center. Of the 1,122 eligible cases, RapidAI detected 93% (109) of MeVOs using CT Perfusion alone, compared to 70% (82) by Viz.ai.

May 20, 2025 — Royal Philips has launched  the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark.

May 19, 2025 — Gradient Denervation Technologies recently announced the company’s pulmonary denervation system has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This program creates an expedited review pathway for devices that have the potential to provide more effective treatment for life-threatening or debilitating conditions and meet FDA’s rigorous standards for safety and efficacy.

May 13, 2025-- GE HealthCare recently announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company’s Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent (UEA). This approval will help improve the clarity and diagnostic accuracy of echocardiograms in pediatric patients, giving cardiologists a fuller picture of ventricular function when assessing possible heart abnormalities or disease. 

May 19, 2025 - Arineta, a provider of cardiovascular imaging solutions, recently announced that its SpotLight Duo cardiac CT scanner has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for low-dose lung cancer screening (LDCT). This clearance allows providers to use a single ultra-fast CT platform for both cardiac and lung imaging and diagnostics, delivering more complete care to high-risk patients.

May 15, 2025 – Royal Philips, a global leader in health technology, has released its 10th annual Future Health Index (FHI) report, highlighting the growing strain on global healthcare systems. The FHI 2025 Report, the largest global survey of its kind analyzing key concerns of healthcare professionals and patients, indicates AI holds promise for transforming care delivery.

May 15, 2025 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, has announced that data from 23 company-sponsored and funded studies, including three late-breaking presentations, will be presented at EuroPCR 2025, May 20-23 in Paris. These studies will feature data from Shockwave’s cardiovascular portfolio, including its market-leading Shockwave Intravascular Lithotripsy (IVL) platform and innovative Reducer technology that are transforming the treatment of cardiovascular disease.1

May 14, 2025 — BrightHeart, a provider of artificial intelligence (AI) solutions for pediatric cardiology and obstetrics, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its second device, B-Right Views.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now